Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
1-year extension study of CRx-102 in active rheumatoid arthritis
2007-004399-38Phase 2Terminated
- Sponsor
- CombinatoRx
- Start
- Feb 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of prednisolone + dipyridamole in rheumatoid arthritis (RA) (2 arms), sponsored by CombinatoRx. Primary endpoints: Long-term safety and tolerability of CRx-102 and Long-term effectiveness of CRx-102. Started Feb 2008; status: terminated.
02
Drugs
prednisolone + dipyridamole
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2007-004399-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004399-38.